Biocon Limited (BIOCON.NS)


NSE - NSE Delayed Price. Currency in INR
962.45-0.50 (-0.05%)
At close: 6:00 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open964.90
Prev Close962.95
Bid962.45 x
Ask0.00 x
Day's Range956.00 - 975.00
52wk Range431.00 - 975.00
1y Target EstN/A
Market Cap188.76B
P/E Ratio (ttm)20.51
BetaN/A
Volume848,970
Avg Vol (3m)1,366,021
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswirelast month

    Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

    BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe.

  • PR Newswire2 months ago

    Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

    BENGALURU, India, HERTFORDSHIRE, England and PITTSBURGH, July 21, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review, Mylan's Marketing Authorization Application (MAA) for our proposed biosimilar Pegfilgrastim, which is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Mylan and Biocon, who have co-developed the proposed biosimilar, received EMA's acceptance of the submission for review. In addition to analytical, functional and pre-clinical data, the application includes clinical data from pivotal Pharmacokinetic / Pharmacodynamic (PK / PD) and confirmatory efficacy, safety and immunogenicity studies completed earlier in 2016.

  • PR Newswire3 months ago

    Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

    BENGALURU, India and FREMONT, Calif., June 23, 2016 /PRNewswire/ -- Biocon Ltd . (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceutical company, and Quark Pharmaceuticals, Inc., a leader in ...